Sema4 has signaled its intent to grow into a juggernaut of precision medicine by going public. The company has raised about $500 million through a business combination completed with CM Life Sciences, a Special Purpose Acquisition Company (SPAC) sponsored by affiliates of noted life sciences investor Eli Casdin’s Casdin Capital and Corvex Management, a hedge fund manager and investment advisor founded by CM’s former chairman Keith A. Meister . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge